Adjunctive therapy with interstitial irradiation for prostate cancer

Area of Science:

• Urology
• Radiation Oncology
• Medical Oncology

Background:

• Prostate cancer staging is crucial for treatment planning.
• Pelvic lymph node status impacts prognosis in localized adenocarcinoma of the prostate.

Purpose of the Study:

• To evaluate the impact of pelvic lymph node involvement on disease progression.
• To assess the efficacy of adjuvant chemotherapy and external beam radiation therapy in managing prostate cancer.

Main Methods:

• Thirty patients with clinically localized prostate adenocarcinoma underwent staging pelvic lymphadenectomy and interstitial irradiation.
• Patients were followed for 18-45 months for disease progression and complications.
• Adjuvant chemotherapy and/or external beam radiation therapy were administered to select patients.

Main Results:

• 53.3% of patients were upstaged to Stage D1 due to pelvic node involvement.
• Stage D1 patients had a higher rate of disease progression (56.3%) and mortality.
• Adjuvant chemotherapy appeared to reduce progression in upstaged patients (33.3% vs. 85.7% without chemotherapy).
• External beam radiation therapy was associated with a high rate of long-term complications (75% of all complications).

Conclusions:

• Pelvic lymph node metastasis is a significant adverse prognostic factor in prostate cancer.
• Adjuvant chemotherapy may offer a survival benefit for node-positive patients.
• External beam radiation therapy, when added to interstitial irradiation, increases complication rates without clear benefit in this cohort.